KCNN4 and ischemic stroke: Moreover, our own group recently demonstrated that both genetic KCa3.1 deletion and pharmacological KCa3.1 blockade with TRAM‐34 started 12 h after reperfusion reduced inflammatory brain cytokine production and microglia activation, and improved neurological deficit in a mouse model of ischemic stroke (Chen et al., 2015).